These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37170847)

  • 1. Margetuximab in HER2-positive metastatic breast cancer.
    Gradishar WJ; O'Regan R; Rimawi MF; Nordstrom JL; Rosales MK; Rugo HS
    Future Oncol; 2023 May; 19(16):1099-1112. PubMed ID: 37170847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Rugo HS; Im SA; Cardoso F; Cortés J; Curigliano G; Musolino A; Pegram MD; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Kaufman B; Yerushalmi R; Fasching PA; Nordstrom JL; Bonvini E; Koenig S; Edlich S; Hong S; Rock EP; Gradishar WJ;
    JAMA Oncol; 2021 Apr; 7(4):573-584. PubMed ID: 33480963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Margetuximab for the treatment of HER2-positive metastatic breast cancer.
    Tarantino P; Morganti S; Uliano J; Giugliano F; Crimini E; Curigliano G
    Expert Opin Biol Ther; 2021 Feb; 21(2):127-133. PubMed ID: 33238772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Margetuximab: First Approval.
    Markham A
    Drugs; 2021 Apr; 81(5):599-604. PubMed ID: 33761116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development and current role of margetuximab for the treatment of breast cancer.
    Tarantino P; Uliano J; Morganti S; Giugliano F; Crimini E; Curigliano G
    Drugs Today (Barc); 2021 Sep; 57(9):551-558. PubMed ID: 34586103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
    Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
    Nur Husna SM; Wong KK
    Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
    Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
    Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy.
    Li J; Lu Q; Zhou H; Xu F; Huang J; Hong R; Wang S
    Anticancer Drugs; 2023 Aug; 34(7):892-895. PubMed ID: 36729856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer.
    Schlam I; Nunes R; Lynce F
    Onco Targets Ther; 2022; 15():471-478. PubMed ID: 35509453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
    Bang YJ; Giaccone G; Im SA; Oh DY; Bauer TM; Nordstrom JL; Li H; Chichili GR; Moore PA; Hong S; Stewart SJ; Baughman JE; Lechleider RJ; Burris HA
    Ann Oncol; 2017 Apr; 28(4):855-861. PubMed ID: 28119295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
    Royce M; Osgood CL; Amatya AK; Fiero MH; Chang CJG; Ricks TK; Shetty KA; Kraft J; Qiu J; Song P; Charlab R; Yu J; King KE; Rastogi A; Janelsins B; Weinberg WC; Clouse K; Borders-Hemphill V; Brown L; Gomez-Broughton C; Li Z; Nguyen TT; Qiu Z; Ly AT; Chang S; Gao T; Tu CM; King-Kallimanis B; Pierce WF; Chiang K; Lee C; Goldberg KB; Leighton JK; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    Clin Cancer Res; 2022 Apr; 28(8):1487-1492. PubMed ID: 34916216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer.
    Alasmari MM
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
    Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
    ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
    Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
    Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
    Chung C; Lam MS
    Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
    Rugo HS; Im SA; Cardoso F; Cortes J; Curigliano G; Musolino A; Pegram MD; Bachelot T; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Schwartz GN; Pluard TJ; Ricci F; Gwin WR; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Gal-Yam EN; Yerushalmi R; Fasching PA; Kaufman PA; Ashley EJ; Perez-Olle R; Hong S; Rosales MK; Gradishar WJ;
    J Clin Oncol; 2023 Jan; 41(2):198-205. PubMed ID: 36332179
    [No Abstract]   [Full Text] [Related]  

  • 19. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report.
    Chang H; Hu T; Hu J; Ding T; Wang Q; Cheng J
    Anticancer Drugs; 2023 Aug; 34(7):883-887. PubMed ID: 36730303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.